Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2025-05-08
2025-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Peripheral Perfusion Index in Weaning From Mechanical Ventilation
NCT03974568
PEEP Influence on Gas Exchange During Early Weaning
NCT02281695
Therapy Study of Automated Protocolized vs. Physician-Directed Non-Protocolized Weaning
NCT00606788
Characterization of Weaning Practices in ICUs of Global South Countries
NCT07337408
Evaluation of Mechanical Power and Ventilator Parameters to Predict Weaning Success in the Intensive Care Unit
NCT07268989
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Readiness for weaning from mechanical ventilation will be evaluated by the same attending intensivist throughout the study, in accordance with the local protocol. Criteria for readiness include resolution of the underlying cause of mechanical ventilation, ability to tolerate temporary discontinuation of mechanical ventilation, absence of frequent endotracheal suctioning needs, adequate oxygenation (PaO₂ \> 60 mmHg with FiO₂ ≤ 0.5 and PEEP ≤ 8 cmH₂O), acceptable pH and PaCO₂ based on the patient's baseline respiratory condition, and stable cardiovascular status. In patients at high risk for upper airway edema, a cuff leak test will be performed by the intensivist.
The spontaneous breathing trial (SBT) will be performed using the Pressure Support (PS) mode with 5 cmH₂O PS and 5 cmH₂O PEEP. After 30 minutes, weaning parameters will be reassessed and the intensivist will make the extubation decision.
SBT failure will be defined by the presence of one or more of the following criteria: altered mental status, respiratory rate \> 35 breaths/min, RSBI \> 105, signs of increased respiratory effort (use of accessory muscles, thoracoabdominal asynchrony, intercostal retractions), SpO₂ \< 90% or PaO₂ \< 60 mmHg on FiO₂ of 0.4, or hemodynamic instability (heart rate \> 140 bpm, systolic blood pressure \> 180 mmHg or \< 90 mmHg, or a change in either \> 20% from baseline).
Patients with successful SBT will be extubated and monitored for 48 hours for the need for reintubation. Supplemental oxygen will be provided via a simple oxygen mask (4-6 L/min) to maintain SpO₂ \> 92%.
The primary outcome is the ability of the Peripheral Perfusion Index (PPI) measured 1 hour after extubation to predict extubation failure within 48 hours.
The secondary outcomes include the predictive ability of PPI measured at the beginning of SBT, at 15 minutes, at the end of SBT, and 2 hours after extubation in identifying patients who will require reintubation within 48 hours.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
patients were monitored for reentubation for 48 hours.
patients were monitored for reentubation for 48 hours.
weaning group
patients were monitored for reentubation for 48 hours.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients over 18 years of age who are planned to undergo extubation following a spontaneous breathing trial (SBT)
* Patients or their legal representatives who provide informed consent to participate in the study
Exclusion Criteria
* Patients with peripheral vascular disease or a history of hand surgery
* Patients who die or cannot be followed up during the study period
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gaziosmanpasa Research and Education Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
veysel Dinç
Assist. Prof.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gaziosmanpaşa Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Gaziosmanpaşa Training and Research Hospital Gaziosmanpaşa Training and Research Hospital
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Gaziosmanpaşa TREH, VD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.